Abstract
Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance EGFR mutations and MET mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for EGFR-mutant non-small-cell lung cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 639-647 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 18 |
Issue number | 6 |
DOIs | |
State | Published - Feb 2022 |
Keywords
- EGFR mutations
- amivantamab
- lazertinib
- non-small-cell lung cancer
- tyrosine kinase inhibitors
ASJC Scopus subject areas
- Oncology
- Cancer Research